Cancer stem cells: A contentious hypothesis now moving forward

Cancer Letters

Volumn 344, Issue 2, 2014, Pages 180-187

  O'Connor, Michael L ^a   Xiang, Dongxi ^a   Shigdar, Sarah ^a   Macdonald, Joanna ^a   Li, Yong ^b   Wang, Tao ^a   Pu, Chunwen ^c   Wang, Zhidong ^c   Qiao, Liang ^d   Duan, Wei ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c Dalian Sixth People's Hospital   (China)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aptamers; Cancer stem cells; Chemoresistance; Clonal evolution; Stemness

Indexed keywords

ABC TRANSPORTER; CELL SURFACE MARKER; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL RENEWAL; CLONAL EVOLUTION; EPIGENETICS; HUMAN; LEUKEMIC STEM CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL RESEARCH; TUMOR MICROENVIRONMENT; XENOTRANSPLANTATION;

APTAMERS; CANCER STEM CELLS; CHEMORESISTANCE; CLONAL EVOLUTION; STEMNESS;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84893710592     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.012     Document Type: Review

References (93)

1. Gilbertson R.J., Graham T.A. Cancer: resolving the stem-cell debate. Nature 2012, 488:462-463.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63(2013):11-30.
3. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
4. Nguyen-Khac F., Lesty C., Eclache V., Couronne L., Kosmider O., Andrieux J., Collonge-Rame M.A., Penther D., Lafage M., Bilhou-Nabera C., Chapiro E., Mozziconacci M.J., Mugneret F., Gachard N., Nadal N., Lippert E., Struski S., Dastugue N., Cabrol C., Bernard O.A. Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer 2010, 49:919-927.
5. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
6. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
7. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
8. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197:461-463.
9. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., Sotiropoulou P.A., Loges S., Lapouge G., Candi A., Mascre G., Drogat B., Dekoninck S., Haigh J.J., Carmeliet P., Blanpain C. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403.
10. Lee H.E., Kim J.H., Kim Y.J., Choi S.Y., Kim S.W., Kang E., Chung I.Y., Kim I.A., Kim E.J., Choi Y., Ryu H.S., Park S.Y. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br. J. Cancer 2011, 104:1730-1738.
11. Wenjing J., Jianhua P., Yue Z., Cho W.C.S., Kunlin J. The implications of cancer stem cells for cancer therapy. Int. J. Mol. Sci. 2012, 13:16636-16657.
12. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
13. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
14. Swords R., Quinn J., Fay M., O'Donnell R., Goldman J., Murphy P.T. CML clonal evolution with resistance to single agent imatinib therapy. Clin. Lab. Haematol. 2005, 27:347-349.
15. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006, 66:1883-1890.
16. Melton D.A., Cowan C. Stemness. Handbook of Stem Cells 2004, Academic Press, Burlington, pp. xxv-xxxi. L. Robert, G. John, H. Brigid, M. Douglas, P. Roger, T. James, W. Michael (Eds.).
17. Fortunel N.O., Otu H.H., Ng H.-H., Chen J., Mu X., Chevassut T., Li X., Joseph M., Bailey C., Hatzfeld J.A., Hatzfeld A., Usta F., Vega V.B., Long P.M., Libermann T.A., Lim B. Comment on " 'Stemness': Transcriptional profiling of embryonic and adult stem cells" and "A stem cell molecular signature". Science 2003, 302:393.
18. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., Melton D.A. Stemness: transcriptional profiling of embryonic and adult stem cells. Science 2002, 298:597-600.
19. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 2010, 20:85-92.
20. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
21. Smalley M., Ashworth A. Stem cells and breast cancer: a field in transit. Nat. Rev. Cancer 2003, 3:832-844.
22. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003, 17:3029-3035.
23. Jamieson C.H., Ailles L.E., Dylla S.J., Muijtjens M., Jones C., Zehnder J.L., Gotlib J., Li K., Manz M.G., Keating A., Sawyers C.L., Weissman I.L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl. J. Med. 2004, 351:657-667.
24. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., Golub T.R., Armstrong S.A. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
25. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.-A., Delaloye J.-F., Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
26. Odoux C., Fohrer H., Hoppo T., Guzik L., Stolz D.B., Lewis D.W., Gollin S.M., Gamblin T.C., Geller D.A., Lagasse E. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res. 2008, 68:6932-6941.
27. Scheel C., Eaton Elinor N., Li Sophia H.-J., Chaffer Christine L., Reinhardt F., Kah K.-J., Bell G., Guo W., Rubin J., Richardson Andrea L., Weinberg Robert A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011, 145:926-940.
28. Vermeulen L., de Sousa Melo F., Richel D.J., Medema J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012, 13:e83-e89.
29. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1889, 8(1989):98-101.
30. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
31. Al-Hajj M., Becker M.W., Wicha M., Weissman I., Clarke M.F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 2004, 14:43-47.
32. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
33. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
34. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
35. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
36. Gonzalez-Moles M.A., Scully C., Ruiz-Avila I., Plaza-Campillo J.J. The cancer stem cell hypothesis applied to oral carcinoma. Oral Oncol. 2013, 49:738-746.
37. Kelly P.N., Dakic A., Adams J.M., Nutt S.L., Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
38. Puglisi M.A., Tesori V., Lattanzi W., Gasbarrini G.B., Gasbarrini A. Colon cancer stem cells: controversies and perspectives. World J. Gastroenterol 2013, 19:2997-3006.
39. De Palma M., Venneri M.A., Galli R., Sergi L.S., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
40. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993, 81:2844-2853.
41. Orkin S.H. Diversification of haematopoietic stem cells to specific lineages. Nat. Rev. Genet. 2000, 1:57-64.
42. Li Z., Li L. Understanding hematopoietic stem-cell microenvironments. Trends Biochem. Sci. 2006, 31:589-595.
43. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA 2004, 101:4966-4971.
44. Chen J., Li Y., Yu T.-S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
45. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
46. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
47. Koike A., Moore G.E., Mendoza C.B., Watne A.L. Heterologous, homologous, and autologous transplantation of human tumors. Cancer 1963, 16:1065-1071.
48. Dieter S.M., Ball C.R., Hoffmann C.M., Nowrouzi A., Herbst F., Zavidij O., Abel U., Arens A., Weichert W., Brand K., Koch M., Weitz J., Schmidt M., von Kalle C., Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011, 9:357-365.
49. Roy S., Majumdar A.P. Cancer stem cells in colorectal cancer: genetic and epigenetic changes. Stem Cell Res. Ther. 2012, (Suppl. 7).
50. De Sousa E.M.F., Vermeulen L., Fessler E., Medema J.P. Cancer heterogeneity-a multifaceted view. EMBO Rep. 2013, 14:686-695.
51. Dexter D.L., Leith J.T. Tumor heterogeneity and drug resistance. Clin. Oncol. 1986, 4:244-257.
52. Rehemtulla A. Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia (New York, N.Y.) 2012, 14:1278-1289.
53. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., Arendt L.M., Kuperwasser C., Bierie B., Weinberg R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108:7950-7955.
54. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
55. Chaffer Christine L., Marjanovic Nemanja D., Lee T., Bell G., Kleer Celina G., Reinhardt F., D'Alessio Ana C., Young Richard A., Weinberg Robert A. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154:61-74.
56. Notta F., Mullighan C.G., Wang J.C., Poeppl A., Doulatov S., Phillips L.A., Ma J., Minden M.D., Downing J.R., Dick J.E. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
57. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13:714-726.
58. Aulmann S., Waldburger N., Penzel R., Andrulis M., Schirmacher P., Sinn H.P. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. Hum. Pathol. 2010, 41:574-581.
59. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
60. Francipane M.G., Chandler J., Lagasse E. Cancer stem cells: a moving target. Curr. Pathobiol. Rep. 2013, 1:111-118.
61. Ghods A.J., Irvin D., Liu G., Yuan X., Abdulkadir I.R., Tunici P., Konda B., Wachsmann-Hogiu S., Black K.L., Yu J.S. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 2007, 25:1645-1653.
62. Resetkova E., Reis-Filho J.S., Jain R.K., Mehta R., Thorat M.A., Nakshatri H., Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat. 2010, 123:97-108.
63. Williams K., Motiani K., Giridhar P.V., Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp. Biol. Med. (Maywood, N.J.) 2013, 238:324-338.
64. Koren A., Motaln H., Cufer T. Lung cancer stem cells: a biological and clinical perspective. Cell Oncol. (Dordrecht) 2013, 36:265-275.
65. Alison M.R., Lin W.R., Lim S.M., Nicholson L.J. Cancer stem cells: in the line of fire. Cancer Treat. Rev. 2012, 38:589-598.
66. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
67. Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., Kwon H.Y., Kim J., Chute J.P., Rizzieri D., Munchhof M., VanArsdale T., Beachy P.A., Reya T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
68. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11:338-351.
69. McAuliffe S.M., Morgan S.L., Wyant G.A., Tran L.T., Muto K.W., Chen Y.S., Chin K.T., Partridge J.C., Poole B.B., Cheng K.H., Daggett J., Cullen K., Kantoff E., Hasselbatt K., Berkowitz J., Muto M.G., Berkowitz R.S., Aster J.C., Matulonis U.A., Dinulescu D.M. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. USA 2012, 109:E2939-E2948.
70. Song Z., Yue W., Wei B., Wang N., Li T., Guan L., Shi S., Zeng Q., Pei X., Chen L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 2011, 6:e17687.
71. Ulasov I.V., Nandi S., Dey M., Sonabend A.M., Lesniak M.S. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol. Med. 2011, 17:103-112.
72. Wang J., Sullenger B.A., Rich J.N. Notch signaling in cancer stem cells. Adv. Exp. Med. Biol. 2012, 727:174-185.
73. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., Sprick M.R., Kemper K., Richel D.J., Stassi G., Medema J.P. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
74. Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2:3.
75. Lou H., Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007, 26:1357-1360.
76. Golebiewska A., Brons N.H., Bjerkvig R., Niclou S.P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011, 8:136-147.
77. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.-M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
78. Triel C., Vestergaard M.E., Bolund L., Jensen T.G., Jensen U.B. Side population cells in human and mouse epidermis lack stem cell characteristics. Exp. Cell Res. 2004, 295:79-90.
79. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2007, 15:504-514.
80. Mak A.B., Blakely K.M., Williams R.A., Penttila P.A., Shukalyuk A.I., Osman K.T., Kasimer D., Ketela T., Moffat J. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J. Biol. Chem. 2011, 286:41046-41056.
81. Waldron N.N., Kaufman D.S., Oh S., Inde Z., Hexum M.K., Ohlfest J.R., Vallera D.A. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 2011, 10:1829-1838.
82. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 2013, 15:338-344.
83. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B., Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 2008, 14:123-129.
84. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
85. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
86. Singh S.R. Gastric cancer stem cells: a novel therapeutic target. Cancer Lett. 2013, 338:110-119.
87. Levina V., Marrangoni A., Wang T., Parikh S., Su Y., Herberman R., Lokshin A., Gorelik E. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 2010, 70:338-346.
88. Shigdar S., Lin J., Li Y., Yang C.J., Wei M., Zhus Y., Liu H., Duan W. Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging. Ther. Deliv. 2012, 3:227-244.
89. Shigdar S., Ward A.C., De A., Yang C.J., Wei M., Duan W. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies. Br. J. Haematol. 2011, 155:3-13.
90. Ng E.W., Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. 2005, 40:352-368.
91. Shigdar S., Lin J., Yu Y., Pastuovic M., Wei M., Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011, 102:991-998.
92. Shigdar S., Qiao L., Zhou S.F., Xiang D., Wang T., Li Y., Lim L.Y., Kong L., Li L., Duan W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett. 2013, 330:84-95.
93. Huang Y.F., Shangguan D., Liu H., Phillips J.A., Zhang X., Chen Y., Tan W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 2009, 10:862-868.